Brady Collins
The Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). It is also used to treat bladder cancer and prevent tuberculous meningitis and miliary disease. The BCG vaccine is injected into the skin and often leaves a scar on the upper arm. However, scar formation is not guaranteed, and the absence of a scar does not indicate that the vaccine failed to provide immunity. The mechanism behind the BCG vaccine's scar formation is not well understood, but it is known to correlate with the immune response to the vaccination.
| Characteristics | Values |
|---|---|
| Scar Formation | Occurs in the majority of people who receive the vaccine |
| Mechanism of Scar Formation | Not well understood |
| Scar Appearance | Raised centre with rounded edges |
| Scar Failure Rate | 8.6% (one study) or 1-20% (other studies) |
| Correlation Between Scar Size and TST Size | Positive correlation (r = 0.401, P = 0.001) |
| Reduction of Scarring | Use vitamin E oil and avoid touching the scab |
Explore related products
What You'll Learn
- The BCG vaccine is primarily used against tuberculosis (TB)
- The vaccine is administered intradermally and can cause scarring
- Scar formation occurs in most people, but not all
- The size of the scar may correlate with the strength of the immune response
- The BCG vaccine is often used to treat bladder cancer
The BCG vaccine is primarily used against tuberculosis (TB)
The Bacille Calmette-Guérin (BCG) vaccine is primarily used against tuberculosis (TB). It is the only vaccine licensed against tuberculosis, a disease that is an ongoing pandemic. The BCG vaccine is the most frequently administered vaccine worldwide today. It is administered as a single shot and is given to infants and small children in countries where TB is prevalent.
The vaccine protects children from getting severe forms of active TB, such as TB meningitis and miliary TB disease. It also has a non-TB-related beneficial effect on child survival. The BCG vaccine may also be considered for healthcare workers, but they should be counselled regarding the risks and benefits associated with both BCG vaccination and the treatment of latent TB infection. Persons who are immunosuppressed, such as those with HIV, or likely to become immunocompressed, such as those who are candidates for organ transplants, should not receive the BCG vaccine.
The BCG vaccine is not generally used in the United States due to the low risk of infection with TB bacteria, its variable effectiveness against adult pulmonary TB, and its potential to cause a false positive TB skin test reaction. However, it is considered for people who meet specific criteria and in consultation with a TB expert. The BCG vaccine has shown a 60 to 80% protective effect in the UK, but trials conducted elsewhere have shown no protective effect. The duration of protection offered by the BCG vaccine is also not clearly known. While some studies have shown protection waning to 59% after 15 years and to zero after 20 years, others have found evidence of protection even 60 years after immunisation.
Regional bone infection (BCG osteomyelitis or osteitis) and disseminated BCG infection are rare but potentially life-threatening complications of the BCG vaccine. When used for bladder cancer, around 2.9% of treated patients discontinue immunotherapy due to a genitourinary or systemic BCG-related infection.
Vaccinations for India: What's the Cost?
You may want to see also
Explore related products
The vaccine is administered intradermally and can cause scarring
The Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). It is also used to treat bladder cancer and offers some protection against Buruli ulcer infection and other nontuberculous mycobacterial infections. The vaccine is typically administered to healthy babies in countries where tuberculosis or leprosy is prevalent. In other areas, only children at high risk are usually immunized.
The BCG vaccine is given intradermally, which means it is injected into the skin. This method of administration can cause scarring in most people who receive it. The scar typically has a raised center with rounded edges. However, scar failure can occur in a small percentage of cases, ranging from 1% to 20% in different studies.
The presence and size of the scar have been linked to the strength of the immune response to the BCG vaccination. While scarring is a common side effect, it is not indicative of the vaccine's effectiveness. The size of the scar does not correlate with the level of immunity provided.
It is important to note that the mechanism behind the formation of the BCG vaccine scar is not yet fully understood. The scarring may be due to the body's immune response to the vaccine rather than the method of injection.
To minimize scarring, it is recommended to avoid touching the scab that forms over the injection site and to apply vitamin E oil to the area.
The TB Vaccine: What's in a Name?
You may want to see also
Explore related products
Scar formation occurs in most people, but not all
The BCG vaccine is primarily used to vaccinate against tuberculosis (TB). It is also used to treat bladder cancer and offers protection against Buruli ulcer infection and other nontuberculous mycobacterial infections. The vaccine is administered intradermally, and in some rare cases, subcutaneously.
The BCG vaccine is the most frequently administered vaccine worldwide. It is injected into the skin, often on the upper arm, leaving a circular scar with a raised centre and rounded edges. However, scar formation is not universal. While the majority of people who receive the vaccine will exhibit scarring, a small minority will not.
There is a notable variation in the BCG scar failure rate, ranging from 1% to 20% in different studies. One study of 70 infants vaccinated within the first month of life found a scar failure rate of 8.6%. Another study of 85 infants found a higher failure rate of 27.1%, with only 25.7% receiving the vaccine within 48 hours of birth. The true magnitude of scar failure is unclear, and it is uncertain whether scar-negative infants need to be monitored.
The presence and size of the scar correlate with the magnitude of the immune response to the BCG vaccination. However, it is important to note that the size of the scar does not indicate the level of immunity provided by the vaccine. The absence of a scar does not necessarily mean that the vaccine failed to provide immunity.
The mechanism underlying the formation of the BCG vaccine scar is not yet fully understood.
Vaccination Requirements for Army Enlistment Explained
You may want to see also
Explore related products
The size of the scar may correlate with the strength of the immune response
The Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). It is also used to prevent childhood tuberculous meningitis and miliary disease and has some effectiveness against Buruli ulcer infection and other nontuberculous mycobacterial infections. Additionally, it is often used as part of the treatment of bladder cancer. The BCG vaccine is the most frequently administered vaccine worldwide today and is recommended by the WHO for all countries with a high incidence of tuberculosis and/or high leprosy burden.
The BCG vaccine is typically administered intradermally, and in rare cases, it may be given subcutaneously. The mechanism underlying the vaccine's telltale scar is not well understood, but scar formation occurs in most people who receive it. The presence and size of the scar have been shown to correlate with the strength of the immune response to the BCG vaccination. This means that a larger scar may indicate a stronger immune response. However, it is important to note that the size of the scar is not the only factor influencing immunity, and other factors such as genetic differences, environmental conditions, and exposure to other bacterial infections also play a role in the overall immune response.
While the BCG vaccine often leaves a scar, scar failure is a known phenomenon, with a prevalence ranging from 1% to 20% in different studies worldwide. In a particular study, 64 out of 70 infants (91.4%) had a visible scar at 12 weeks post-vaccination, indicating a scar failure rate of 8.6%. The mean scar size was 4.93 mm, and there was a significant correlation between scar size and tuberculin skin test (TST) reaction size.
It is worth noting that the smallpox vaccine, which was previously a part of routine childhood vaccination in the United States and other countries, also left a similar scar. However, smallpox was eradicated in 1979, and the last smallpox vaccine was administered in the U.S. in 1972. Therefore, it is unlikely that anyone under the age of 42 has a smallpox vaccine scar.
Vaccinated and Exposed: Do I Need to Quarantine?
You may want to see also
Explore related products
The BCG vaccine is often used to treat bladder cancer
The Bacillus Calmette–Guérin (BCG) vaccine is a live attenuated strain of Mycobacterium bovis. It was first developed at the Pasteur Institute in 1921 by Albert Calmette and Camille Guérin. The BCG vaccine is primarily used to vaccinate children against tuberculosis, offering modest protection from the disease, particularly its severe forms.
However, the BCG vaccine is also used to treat non-muscle invasive bladder cancer (NMIBC). It is the only agent approved by the US Food and Drug Administration for primary therapy of carcinoma in situ (CIS) of the bladder. BCG is often used after TURBT surgery to prevent cancer recurrence. It is administered in liquid form directly into the bladder via a flexible catheter. The medicine then alerts the immune system to attack the cancer cells.
BCG is the standard treatment for early-stage bladder cancer, specifically for high-risk non-muscle invasive bladder cancer. It is recommended for most patients with high-risk NMIBC. BCG treatment can eradicate this type of cancer in 70% of patients who meet specific criteria. It is also used for stage 0is and stage 1 cancers, which have spread only into the lining of the bladder.
While the BCG vaccine is a successful treatment for bladder cancer, it can cause side effects. Discomfort or burning while urinating may occur, as the treatment may irritate the bladder. These side effects typically last for two to three days. Long-term side effects are rare, but if BCG enters the bloodstream, it can cause a serious infection, even years after treatment. BCG may also cause a strong local reaction if it comes into contact with a sore or cut.
In addition to its use in treating tuberculosis and bladder cancer, the BCG vaccine is well known for leaving a circular scar on the upper arm of those who receive it. Scar formation occurs in the majority of people vaccinated, and the size of the scar correlates with the magnitude of the immune response to the vaccination. However, scar failure is possible, with a rate of 8.6% reported in one study.
Ask Cities: Do They Vaccinate Immigrants?
You may want to see also
Frequently asked questions
No, it is uncommon but possible for the BCG vaccine to not leave a scar.
The reason for scar absence is unclear, but scar failure rates vary from 1% to 20% in different studies.
The size of the scar has been shown to correlate with the magnitude of the immune response to BCG vaccination. However, the size of the scar does not determine immunity.
A BCG vaccine scar tends to have a raised centre with rounded edges.
You can lessen the scarring by using vitamin E oil and not touching the scab that forms over the vaccination site.
